Anticipated Surge in Global Gene Panel Market: Fuelled by Rising Prevalence of Genetic Disorders – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The Global Gene Panel Market to 2028 report has been added to ResearchAndMarkets.com’s offering.


The global gene panel market is poised for impressive growth during the forecast period, driven by the increasing prevalence of genetic disorders such as Down syndrome, sickle cell disease, Tay-Sachs disease, and others.

Growing healthcare awareness among the population and a rising demand for early diagnosis prompt many couples to opt for genetic testing before planning a family or during pregnancy, thereby bolstering the market in the foreseeable future. The adoption of gene panels is also on the rise due to the technique’s cost-effectiveness, fast, and accurate testing, propelling market expansion. Additionally, with an improving healthcare infrastructure and increased investments in research and development related to gene panels, lucrative opportunities for market growth are expected to abound in the coming years.

Elevated Incidence of Chronic Diseases

The escalating incidence of chronic diseases, including cancer, congenital diseases, heart attacks, and arthritis, is expected to drive the gene panel market growth during the forecast period. The demand for gene panel testing surges in response to the increasing disorders caused by genetic mutations. This diagnostic technique analyzes multiple genes for cancer-associated alterations simultaneously. Key players in the field are witnessing high demand for gene panels to develop and launch effective cancer therapies, further fostering market growth.

The global cancer observatory reported approximately 19,292,789 new cancer cases worldwide, with 9,227,484 cases in females and 10,065,305 cases in males. The rising prevalence of cancer is likely to increase the demand for gene panels. Despite the high cost, genetic testing is primarily conducted on patients with a high risk of developing specific types of cancer due to hereditary factors, including lifestyle choices such as smoking, unhealthy habits, lack of physical activity, and alcohol consumption. According to the World Health Organization (WHO), about 295,000 newborns worldwide die within 28 days of birth annually due to congenital anomalies.

Technological Advancements

The growing demand for advanced medical testing and personalized medicines in clinical diagnosis creates attractive opportunities for market growth in the forecast period. Genetic disorders are currently prevalent in the geriatric population, significantly supporting the expansion of the gene panel market.

Numerous global companies are focused on developing new and advanced gene panels, further driving market growth in the coming years. The increasing initiative and investment by private and government organizations in developing new technologies serve as significant factors propelling market growth. Birth defects affect approximately 1 in every 33 babies born in the United States each year, amounting to around 120,000 babies.

Market Segmentation

The global gene panel market can be segmented based on components, techniques, design, applications, end-users, and regions. Components include Test Kits and Testing Services, while techniques comprise Amplicon Based Approach and Hybridization Based Approach. Design options include Predesigned Gene Panels and Customized Gene Panels, and applications encompass Cancer Risk Assessment, Diagnosis of Congenital Diseases, Pharmacogenetics, and Others. End-users are categorized as Academic & Research Institutes, Hospital & Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies.

Regionally, North America dominates the market among Asia Pacific, Europe, Middle East & Africa, and South America. The United States leads the global gene panel market due to the growing demand for gene panel techniques in response to the rising cancer cases worldwide. The American Cancer Society (ACS) predicts over 1.9 million new cancer cases in the United States in 2022.

Key Topics Covered

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Gene Panel Market Outlook

6. North America Gene Panel Market Outlook

7. Europe Gene Panel Market Outlook

8. Asia-Pacific Gene Panel Market Outlook

9. South America Gene Panel Market Outlook

10. Middle East and Africa Gene Panel Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. Competitive Landscape

14. Strategic Recommendations

A selection of key companies profiled in this report includes:

Illumina, Inc.

Agilent Technologies, Inc.

Thermo Fischer Scientific, Inc.

QIAGEN NV

Eurofins Scientific SE

Foundation Medicine Inc.

Guardant Health, Inc.

Myriad Genetic Laboratories Inc.

Bio-Rad Laboratories, Inc.

F. Hoffmann-La Roche AG

For more information about this report visit https://www.researchandmarkets.com/r/ngs6c1

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Businesswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, businesswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.